Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Ra Medical Systems — Investor Presentation (January 2021)
25 slides from Catheter Precision's investor presentation, Jan 5, 2021
Slide 1: Corporate Presentation
Ra Medical Systems, Inc. NYSE American: RMED Corporate Presentation dated January 5, 2021 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra Medical Systems, Inc. (the “Company”) and involve known and unknown risks, uncertainties and othe
Slide 3: Highlights: Pharos growth strategy to build on annual revenue rate
Focused on developing Pharos growth strategy to build on ~$5-6 million annual revenue rate Highlights * IDE trial for atherectomy indication in process
Slide 4: DABRA and Pharos excimer laser platform
DABRA—Excimer laser that utilizes disposable catheters for crossing total chronic occlusions (CTOs) and ablating a channel in occlusive peripheral vascular disease. DABRA is used as a tool to treat peripheral artery disease (PAD), a form of peripheral vascular disease. Photoablation to disintegrate
Slide 5: Peripheral Artery Disease
Peripheral Artery Disease Only 20 to 30% of peripheral artery disease patients are actively being treated
Slide 6: Large US Addressable Market Opportunity
Large US Addressable Market Opportunity PREVALENCE TREATED PATIENTS MARKET OPPORTUNITY Current US Market Opportunity KEY DRIVER >17 Million PAD Sufferers in the US Only 20–30% of PAD Patients actively treated Annual US TAM Opportunity >$550 million1 For U.S. PAD atherectomy, based on third-party res
Slide 7: DABRA Technology and Mechanism of Action
DABRA Technology and Mechanism of Action DABRA Technology 308 nanometer excimer laser system Unique liquid-filled, full aperture ratio catheter High quality lumen Minimizes mechanical or thermal trauma Mechanism of Action Photoablation Removes blockages by breaking the bonds of the obstructing plaqu
Slide 8: DABRA Advantages
DABRA Advantages s, Clearance and Reimbursement + USFDA510{k) clearance for crossing CTOs and ablating a channel in occlusive peripheral vascular disease + USFDA IDE study underway to obtain an atherectomy indication + CE Mark for laser atherectomy ‘+ Established reimbursement for Office-Based Labs
Slide 9: Clinically Demonstrated Solutions
Clinically Demonstrated Solutions Safety Record Pivotal Study1 Multi-site study at four sites in US and Mexico Enrolled 64 patients with target blockage refractory to guidewire crossing Primary Efficacy Endpoint: Successful crossing of target lesion based on angiographic analysis at time of procedur
Slide 10: DABRA Will Target Office-Based Labs
DABRA Will Target Office-Based Labs We believe our solution expands provider economics
Slide 11: Engineering Efforts Focused on Three Initiatives to Improve DABRA
Engineering Efforts Focused on Three Initiatives to Improve DABRA’s Performance Extend shelf life 6 months minimum with target 12 months or greater Improve deliverability Develop a catheter with an enhanced outer-jacket to allow physicians to better access difficult anatomy Develop guidewire compati
Slide 12: FDA-Approved IDE Atherectomy Indication Study Underway
An FDA-Approved IDE Atherectomy Indication Study is Underway Primary safety endpoint: The incidence of 30-day Major Adverse Events (MAEs) as adjudicated by the Clinical Events Committee (CEC) : All-cause mortality, Unplanned major target limb amputation (at or above the ankle), and/or Clinically dri
Slide 13: Pharos Excimer Laser
Pharos Excimer Laser Used by Physicians to Treat Chronic Skin Diseases + Psoriasis—chronic autoimmune disorder that causes cells to rapidly accumulate and affects the surface of the skin causing scales and red patches * Vitiligo—autoimmune condition causing the skin to turn white due to the loss of
Slide 14: Pharos Science, Advantages and Reimbursement
Pharos Science, Advantages and Reimbursement Pharos Science Same laser platform as DABRA 308-nanometer laser—the center of action spectrum for most immune-mediated inflammatory diseases Does not use heat or ablate lesions—treatments are generally painless Adjustable aiming beam accurately targets on
Slide 15: Fully Operational Manufacturing Facility
Fully Operational Manufacturing Facility Carlsbad, CA Sizable capacity for laser and catheter production 41,000 sq. ft. Carlsbad, CA with three controlled environments manufacturing facility fully staffed and operational Existing facility expected to be capable of manufacturing > 400 lasers/year and
Slide 16: Intellectual Property Portfolio
Intellectual Property Portfolio Patents covering several aspects of the laser systems and delivery device The Company believes that its intellectual property comprises novel and useful inventions that can be protected by patents, and as such, has filed patent applications directed to innovative meth
Slide 17: Management Team
Management Team 25 years med-tech experience, including COO of Spectranetics which was. ‘Sequies by Philips for >$2 bilon and CEO of Atheromed,a venture capita Will McGuire Chief Executive Officer backed peripheral atherectomy company. Also held senior roles at Voleano Corporation, Covidien, and Gul
Slide 18: Financial Overview
Financial Overview
Slide 19: Results of Operations
Results of Operations * Adjusted EBITDA is a non-GAAP measure and is calculated as net profit (loss) excluding interest income (expense), income tax expense and certain recurring, non-cash charges such as depreciation and amortization of long-lived assets as well as stock-based compensation expenses
Slide 20: Financial Position
Financial Position We define working capital as current assets minus current liabilities
Slide 21: Pharos growth strategy to build on annual revenue rate
Focused on developing Pharos growth strategy to build on ~$5-6 million annual revenue rate Highlights * IDE trial for atherectomy indication in process
Slide 22: Key Vascular Milestones
Key Vascular Milestones 2020 2021 2022 Limited, preliminary accelerated aging tests on four lots support 6 months or longer shelf life 20 subjects enrolled as of December 31, 2020 (3) Timing of study enrollment uncertain due to unpredictable ongoing impact of COVID-19
Slide 23: Appendix
Appendix
Slide 24: Reconciliation of Net loss to Adjusted EBITDA
Reconciliation of Net loss to Adjusted EBITDA
Slide 25: Board of Directors
Board of Directors ‘Martin Colombatto Chairman. Former VP and General Manager af Broadcom William Enquist Former President of Global Endoscopy of Stryker Will MeGuire Chiet Executive Oficer, Ra Medical Former CEO Second Sight, former executive at Covidien, AtheroMed, Spectranetics iard Mejia Former
Ra Medical Systems — Investor Presentation (January 2021) on 6ix